Wir verwenden Cookies und Analyse-Tools, um die Nutzerfreundlichkeit der Internet-Seite zu verbessern und für Marketingzwecke. Wenn Sie fortfahren, diese Seite zu verwenden, nehmen wir an, dass Sie damit einverstanden sind. Zur Datenschutzerklärung.
SB-269,970
CHF 57.30
Auf Lager
SKU
7EHCJAITT4S
1 Verfügbar 
Geliefert zwischen Do., 13.11.2025 und Fr., 14.11.2025
Details
Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. SB-269,970 is a drug and research chemical developed by GlaxoSmithKline used in scientific studies. It was previously believed to act as a selective 5-HT7 receptor antagonist (or possibly inverse agonist), but a subsequent discovery showed that it also potently blocks the 2-adrenergic receptor. The new finding has raised significant concerns about studies using SB-269,970 as a specific serotonin receptor antagonist. SB-269,970 is used to study the 5-HT7 receptors which are thought to be involved in the function of several areas of the brain such as the hippocampus and thalamus, and regulation of dopamine release in the ventral tegmental area. Possible therapeutic uses for SB-269,970 and other 5-HT7 antagonists include the treatment of anxiety and depression, and nootropic effects have also been noted in animal studies.
Weitere Informationen
- Allgemeine Informationen
- GTIN 09786130968724
- Editor Lambert M. Surhone, Miriam T. Timpledon, Susan F. Marseken
- Genre Chemie
- Größe H220mm x B220mm
- EAN 9786130968724
- Format Fachbuch
- Titel SB-269,970
- Herausgeber Betascript Publishing
- Anzahl Seiten 140
Bewertungen
Schreiben Sie eine Bewertung
